Highlight
– The COMPARE-TAVI 1 trial is a rigorous, randomized, non-inferiority study comparing the contemporary SAPIEN 3/SAPIEN 3 Ultra with the novel Myval and Myval Octacor THVs.
– At 1 year, the Myval valve was demonstrated to be non-inferior to the established SAPIEN 3 valves for a composite endpoint including death, stroke, moderate/severe aortic regurgitation, and haemodynamic valve deterioration.
– The trial enrolled over 1000 patients across multiple Danish centers, representing an all-comers transfemoral TAVI population.
– Procedural characteristics and clinical outcomes support the Myval’s role as an effective alternative to SAPIEN 3 valves in routine clinical practice.
